Document Detail


Transcription coactivator mediator subunit MED1 is required for the development of fatty liver in the mouse.
MedLine Citation:
PMID:  21480322     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Peroxisome proliferator-activated receptor-γ (PPARγ), a nuclear receptor, when overexpressed in liver stimulates the induction of adipocyte-specific and lipogenesis-related genes and causes hepatic steatosis. We report here that Mediator 1 (MED1; also known as PBP or TRAP220), a key subunit of the Mediator complex, is required for high-fat diet-induced hepatic steatosis as well as PPARγ-stimulated adipogenic hepatic steatosis. Mediator forms the bridge between transcriptional activators and RNA polymerase II. MED1 interacts with nuclear receptors such as PPARγ and other transcriptional activators. Liver-specific MED1 knockout (MED1(ΔLiv) ) mice, when fed a high-fat (60% kcal fat) diet for up to 4 months failed to develop fatty liver. Similarly, MED1(ΔLiv) mice injected with adenovirus-PPARγ (Ad/PPARγ) by tail vein also did not develop fatty liver, whereas mice with MED1 (MED1(fl/fl) ) fed a high-fat diet or injected with Ad/PPARγ developed severe hepatic steatosis. Gene expression profiling and northern blot analyses of Ad/PPARγ-injected mouse livers showed impaired induction in MED1(ΔLiv) mouse liver of adipogenic markers, such as aP2, adipsin, adiponectin, and lipid droplet-associated genes, including caveolin-1, CideA, S3-12, and others. These adipocyte-specific and lipogenesis-related genes are strongly induced in MED1(fl/fl) mouse liver in response to Ad/PPARγ. Re-expression of MED1 using adenovirally-driven MED1 (Ad/MED1) in MED1(ΔLiv) mouse liver restored PPARγ-stimulated hepatic adipogenic response. These studies also demonstrate that disruption of genes encoding other coactivators such as SRC-1, PRIC285, PRIP, and PIMT had no effect on hepatic adipogenesis induced by PPARγ overexpression. Conclusion: We conclude that transcription coactivator MED1 is required for high-fat diet-induced and PPARγ-stimulated fatty liver development, which suggests that MED1 may be considered a potential therapeutic target for hepatic steatosis. (HEPATOLOGY 2011;).
Authors:
Liang Bai; Yuzhi Jia; Navin Viswakarma; Jiansheng Huang; Aurore Vluggens; Nathan E Wolins; Nadereh Jafari; M Sambasiva Rao; Jayme Borensztajn; Gongshe Yang; Janardan K Reddy
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Hepatology (Baltimore, Md.)     Volume:  53     ISSN:  1527-3350     ISO Abbreviation:  Hepatology     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-04-11     Completed Date:  2011-06-14     Revised Date:  2012-04-04    
Medline Journal Info:
Nlm Unique ID:  8302946     Medline TA:  Hepatology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1164-74     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 American Association for the Study of Liver Diseases.
Affiliation:
Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL; Laboratory of Animal Fat Deposition and Muscle Development, College of Animal Science and Technology, Northwest A&F University, Shaanxi, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Dietary Fats / administration & dosage
Fatty Liver / etiology*
Gene Expression Profiling
Genes, Regulator
Mediator Complex Subunit 1 / deficiency,  physiology*
Mice
PPAR gamma / biosynthesis,  pharmacology
Grant Support
ID/Acronym/Agency:
DK083163/DK/NIDDK NIH HHS; DK56351/DK/NIDDK NIH HHS; GM23750/GM/NIGMS NIH HHS; R01 DK083163-08/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Dietary Fats; 0/Mediator Complex Subunit 1; 0/PPAR gamma
Comments/Corrections
Erratum In:
Hepatology. 2011 Sep 2;54(3):1114

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepa...
Next Document:  Interferon-? and interferon-? signaling is not affected by interferon-induced refractoriness to inte...